Phase II study of a four-week hypofractionated external beam radiotherapy regimen for prostate cancer: report on acute toxicity.
暂无分享,去创建一个
Guy Storme | Guy Soete | Stefano Arcangeli | W. De Neve | V. Fonteyne | G. Soete | G. Storme | S. Arcangeli | G. De Meerleer | G. Arcangeli | V. Landoni | Gert De Meerleer | Wilfried De Neve | Giorgio Arcangeli | Valeria Landoni | Valerie Fonteyne
[1] E. Hall,et al. Radiobiology for the radiologist , 1973 .
[2] R. Fraser,et al. Evidence for efficacy without increased toxicity of hypofractionated radiotherapy for prostate carcinoma: early results of a Phase III randomized trial. , 2003, International journal of radiation oncology, biology, physics.
[3] X. Allen Li,et al. HOW LOW IS THE / RATIO FOR PROSTATE CANCER? , 2003 .
[4] V. Khoo,et al. Hypofractionated conformal radiotherapy in carcinoma of the prostate: five-year outcome analysis. , 2002, International journal of radiation oncology, biology, physics.
[5] H. Bartelink,et al. Fractionation in radiotherapy. , 1994, Cancer treatment reviews.
[6] Roberto Orecchia,et al. Finding dose-volume constraints to reduce late rectal toxicity following 3D-conformal radiotherapy (3D-CRT) of prostate cancer. , 2003, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[7] Michael J. Zelefsky,et al. High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. , 2002, International journal of radiation oncology, biology, physics.
[8] J. Fowler,et al. New data on the value of α/β—evidence mounts that it is low , 2004 .
[9] W. Tomé,et al. A Multi-Institutional Phase I/II Trial of Dose-per-fraction Escalation for Localized Prostate Cancer , 2005 .
[10] D. Chan,et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. , 1993, The Journal of urology.
[11] L. Gras,et al. Estimation of the incidence of late bladder and rectum complications after high-dose (70-78 GY) conformal radiotherapy for prostate cancer, using dose-volume histograms. , 1998, International journal of radiation oncology, biology, physics.
[12] H. Kal,et al. HOW LOW IS THE / RATIO FOR PROSTATE CANCER? , 2003 .
[13] G H Fletcher,et al. Changes in early and late radiation responses with altered dose fractionation: implications for dose-survival relationships. , 1982, International journal of radiation oncology, biology, physics.
[14] Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. , 2005 .
[15] T. Pajak,et al. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) , 1995, International journal of radiation oncology, biology, physics.
[16] D J Brenner,et al. Fractionation and protraction for radiotherapy of prostate carcinoma. , 1999, International journal of radiation oncology, biology, physics.
[17] W. De Neve,et al. Intensity-modulated radiotherapy as primary treatment for prostate cancer: acute toxicity in 114 patients. , 2004, International journal of radiation oncology, biology, physics.
[18] George Starkschall,et al. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. , 2002, International journal of radiation oncology, biology, physics.
[19] R. Pötter,et al. Rectal sequelae after conformal radiotherapy of prostate cancer: dose-volume histograms as predictive factors. , 2001, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[20] Rick Chappell,et al. Is α/β for prostate tumors really low? , 2001 .
[21] B Pickett,et al. Indications for and the significance of seminal vesicle irradiation during 3D conformal radiotherapy for localized prostate cancer. , 1994, International journal of radiation oncology, biology, physics.
[22] A Pollack,et al. Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial. , 2000, International journal of radiation oncology, biology, physics.
[23] E. B. Butler,et al. Intensity-modulated radiation therapy (IMRT) for prostate cancer with the use of a rectal balloon for prostate immobilization: acute toxicity and dose-volume analysis. , 2001, International journal of radiation oncology, biology, physics.
[24] D. Brenner,et al. In response to Drs. King and Mayo: low α/β values for prostate appear to be independent of modeling details1 , 2000 .
[25] P. Rust,et al. Dose-volume relationship for acute side effects during high dose conformal radiotherapy for prostate cancer. , 2002, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[26] Patrick A Kupelian,et al. Hypofractionated intensity-modulated radiotherapy (70 gy at 2.5 Gy per fraction) for localized prostate cancer: long-term outcomes. , 2005, International journal of radiation oncology, biology, physics.
[27] M. Barry,et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. , 1992, The Journal of urology.
[28] Dirk Verellen,et al. Clinical use of stereoscopic X-ray positioning of patients treated with conformal radiotherapy for prostate cancer. , 2002, International journal of radiation oncology, biology, physics.
[29] P. Lattuada,et al. Is the alpha-beta ratio of prostate cancer really low? A prospective, non-randomized trial comparing standard and hyperfractionated conformal radiation therapy. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[30] F. Bartholomeusz,et al. Anorectal Dysfunction Increases with Time Following Radiation Therapy for Carcinoma of the Prostate , 2004, American Journal of Gastroenterology.
[31] A. Swan,et al. Carcinoma of prostate treated by radical external beam radiotherapy using hypofractionation. Twenty-two years' experience (1962-1984). , 1990, Urology.
[32] A. Nahum,et al. Incorporating clinical measurements of hypoxia into tumor local control modeling of prostate cancer: Implications for the α/β ratio , 2003 .
[33] Daniel W. Miller,et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. , 2005, JAMA.
[34] G Starkschall,et al. Conventional vs. conformal radiotherapy for prostate cancer: preliminary results of dosimetry and acute toxicity. , 1996, International journal of radiation oncology, biology, physics.
[35] Filip Claus,et al. Interobserver Delineation Variation Using CT versus Combined CT + MRI in Intensity–Modulated Radiotherapy for Prostate Cancer , 2005, Strahlentherapie und Onkologie.
[36] P. Koper,et al. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. , 2005, International journal of radiation oncology, biology, physics.
[37] D. Brenner,et al. Direct evidence that prostate tumors show high sensitivity to fractionation (low α/β ratio), similar to late-responding normal tissue , 2002 .
[38] Franca Foppiano,et al. Relationships between DVHs and late rectal bleeding after radiotherapy for prostate cancer: analysis of a large group of patients pooled from three institutions. , 2002, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[39] M. Roach,et al. Re: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. , 1993, The Journal of urology.